In a recent meta-analysis of 20 studies including 1,312 anti-HBc-positive lymphoma patients treated with rituximab-containing chemotherapy, the HBV reactivation rate was 9.0% (95% CI [5%, 15%]) [36]. Here, KRT88P is linked to lymphoma.